Twenty four new l-aminoacyl-2,3-dihydro-4( III)-quinazolinone derivatives were prepared and evaluated for their pharmacological properties. The compounds with a cyclic amino group showed a choleretic activity. Some substances displayed also antifibrillatory and antiphlogistic activity.
Our investigations into the synthesis of medicinal products, based on the concept of a 1 supporting ' moiety, have been discussed in detail by one of us in a lecture presented before the 2nd Convention of the Italian Society of Pharmaceutical Sciences, 27-29 May 1955.1 The theory of the 1 supporting ' moiety may be explained as follows:(1) There are certain molecules, which we call 1 supporting ' moieties, which can be modified by the introduction of certain radicals. These radicals direct the activity of the molecule.(2) The ' supporting ' moiety must have a distinct affinity for the biological substrate and, therefore, molecules which already possess significant biological activity are most suitable for use as ' supporting ' moieties.(3) The introduction of particular chemical radicals on these so-called 1 supporting '
A series of ó-nitro-2-furaldehyde semicarbazones and thiosemicarbazones has been synthesized. All compounds exhibited an antibacterial activity in vitro comparable to that of ")-mtm-2-furaldehyde semicarbazone (12) and thiosemicarbazone (13). Several thiosemicarbazones had antifungal in vitro activity against Trichophyton, mentagrophytes and Candida albicans while 13 had no activity. Compounds 2 and 9 showed significant in vivo activity in the mouse against Micrococcus pyogenes, whereas 12 was not active. Some other compounds were active against. Trypanosoma congolensc in vivo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.